中国365bet中文官网

Lighting up Alzheimer鈥檚-related proteins to allow for earlier disease detection

PressPacs

FOR IMMEDIATE RELEASE


ACS Sensors

Amyloids, shown here surrounding a brain cell, can be easily lit up and detected using a new fluorescent sensor array.
Signal Scientific Visuals/Shutterstock.com

Many neurodegenerative diseases, including Alzheimer鈥檚 and Parkinson鈥檚, are difficult to diagnose before symptoms begin to appear. However, disease-related biomarkers such as aggregated proteins called amyloids could provide important insight much earlier, if they can be readily detected. Researchers publishing in ACS Sensors have developed one such method using an array of sensor molecules that can light up amyloids. The tool could help monitor disease progression or distinguish between different amyloid-related conditions.

鈥疦eurodegenerative diseases typically involve a breakdown of communication within the brain that is often caused by 鈥渟ticky鈥� clumps of misfolded proteins called amyloids that interrupt signal transfer. These amyloids are thought to be closely related to the progression of Alzheimer鈥檚 disease, so they could be used as a means of early diagnosis to expand treatment options. Currently, radioimaging techniques including positron emission tomography (PET) scans can detect amyloids, but these methods rely on sophisticated equipment and typically focus on one of several amyloids involved in the disease. Instead, fluorescence imaging techniques have been explored as a simpler, yet still sensitive, means of detecting multiple specific amyloids. So, Margaret Sunde, Elizabeth New, Amandeep Kaur and colleagues wanted to develop a fluorescent sensor array for amyloids to monitor Alzheimer鈥檚 and other disease progression and to distinguish these atypical amyloids from similar, naturally occurring amyloid-forming proteins.

The team combined five coumarin-based molecular probes, each of which fluoresced to a different degree when it encountered the amyloids, into a sensor array. However, the team found that using just two of the probes with the strongest fluorescence responses still offered a high level of sensitivity and an identifiable fluorescent 鈥渇ingerprint鈥� for the individual amyloids.聽

The two-probe array was added to a sample mixture mimicking biological fluids containing molecules that could potentially interfere with sensing. Regardless, the array maintained a high sensitivity and selectivity. Its performance was also tested on samples taken from the brains of mouse models of Alzheimer鈥檚. The team observed that the fluorescence patterns differed between early (at age 6 months) and later (at age 12 months) stages of the disease. Additionally, a unique fluorescence fingerprint was generated for three amyloids typically involved in Alzheimer鈥檚, another disease-associated amyloid and five naturally occurring 鈥渇unctional amyloids鈥� not involved in the disease. The researchers say that this tool could be used to distinguish between closely related amyloids and could inform new approaches for earlier and more confident diagnosis of amyloid-related diseases.

The authors acknowledge funding from the Australian Research Council and the National Health and Medical Research Council.

###

The American Chemical 中国365bet中文官网 (ACS) is a nonprofit organization founded in 1876 and chartered by the U.S. Congress. ACS is committed to improving all lives through the transforming power of chemistry. Its mission is to advance scientific knowledge, empower a global community and champion scientific integrity, and its vision is a world built on science. The 中国365bet中文官网 is a global leader in promoting excellence in science education and providing access to chemistry-related information and research through its multiple research solutions, peer-reviewed journals, scientific conferences, e-books and weekly news periodical聽Chemical & Engineering News. ACS journals are among the most cited, most trusted and most read within the scientific literature; however, ACS itself does not conduct chemical research. As a leader in scientific information solutions, its CAS division partners with global innovators to accelerate breakthroughs by curating, connecting and analyzing the world鈥檚 scientific knowledge. ACS鈥� main offices are in Washington, D.C., and Columbus, Ohio.

Registered journalists can subscribe to the to access embargoed and public science press releases. For media inquiries, contact newsroom@acs.org.

Note: ACS does not conduct research but publishes and publicizes peer-reviewed scientific studies.

Media Contact

ACS Newsroom
newsroom@acs.org

Related Content